Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by DNAtrix, Inc.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
DNAtrix, Inc.
ClinicalTrials.gov Identifier:
NCT02798406
First received: June 9, 2016
Last updated: March 10, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2020
  Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)